NEW YORK ( TheStreet) -- Shares of Vical ( VICL) tumbled in late trades on Thursday after the San Diego-based biotech announced plans for a dilutive stock offering. The company didn't specify how many shares it expects to sell or at what price. The offering is being made under shelf registration statements filed in May 2009 and January 2010 that have subsequently been declared effective by the Securities and Exchange Commission. In its regulatory filing related to the offering, Vical said it plans to use the proceeds of the sale for general corporate purposes. The stock was last quoted at $3.78, down 11.7%, on volume of nearly 110,000, according to Nasdaq.com. Based on Thursday's regular session close at $4.28, the shares have doubled in the past year, although the peak of $5.30 came back in late July 2011. Vical develops products based upon patented DNA-delivery technology. Its pipeline includes Allovectin, a proposed melanoma treatement in phase III trials; and TransVax, which is for use by hematopoietic stem cell transplant recipients.
The company noted, however, that sales of components for 3G/4G smartphones rose 16% sequentially in the December quarter, and said it expects "normal seasonality" in the March-ending quarter. It plans to report its full third-quarter results on Jan. 24, and provide further guidance at that time. The news weighed on other chip makers, such as TriQuint Semiconductor ( TQNT), which lost nearly 4% to $4.76 on volume of more than 85,000; and SkyWorks Solutions ( SWKS), which fell 3% to $16.60 with in excess of 55,000 shares changing hands. Other stocks making news after the closing bell included Integra LifeSciences ( IART), which forecast weaker than expected fourth-quarter results and said it's received a warning letter from the Food and Drug Administration related to quality systems and compliance issues at a collagen manufacturing facility in Plainsboro, NJ; ViroPharma ( VPHM), which said it sees sales ranging from $600 million to $660 million in 2012 vs. current consensus estimate of $593.2 million; and Ruby Tuesday ( RT), which gave a below-consensus outlook for its fiscal third quarter ending in February, saying it sees earnings of 12 to 16 cents a share vs. the average analysts' view of 27 cents a share because of increased advertising expenses. -- Written by Michael Baron in New York. >To contact the writer of this article, click here: Michael Baron. >To submit a news tip, send an email to: firstname.lastname@example.org